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Abstract
Objectives—The population of older patients with schizophrenia is increasing. This study
describes health outcomes, utilization, and costs over 10 years in a sample of older patients with
schizophrenia compared to older patients without schizophrenia.
Design, Setting, Participants—An observational cohort study of 31,588 older adults (mean
age 70.44 years) receiving care from an urban public health system, including a community
mental health center, during 1999–2008. 1635 (5.2%) were diagnosed with schizophrenia and 757
(2.4%) had this diagnosis confirmed in the community mental health center. Patients’ electronic
medical records were merged with Medicare claims, Medicaid claims, the Minimum Dataset, and
the Outcome and Assessment Information Set. Information on medication use was not available.
Measurements—Rates of comorbid conditions, health care utilization, costs, and mortality.
Results—Patients with schizophrenia had significantly higher rates of congestive heart failure
(45.05% v. 38.84%), chronic obstructive pulmonary disease (52.71% v. 41.41%), and
hypothyroidism (36.72% v. 26.73%) than the patients without schizophrenia (p<0.001). They had
significantly lower rates of cancer (30.78% v. 43.18%) and significantly higher rates of dementia
(64.46% v. 32.13%). The patients with schizophrenia had significantly higher mortality risk (HR:
1.25, CI: 1.07–1.47) than the patients without schizophrenia. They also had significantly higher
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rates of health care utilization. The mean costs for Medicare and Medicaid were significantly
higher for the patients with schizophrenia than for the patients without schizophrenia.
Conclusions—The management of older adult patients with schizophrenia is creating a serious
burden for our health care system, requiring the development of integrated models of health care.
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Objective
In a 1999 consensus statement Jeste and his colleagues predicted an impending crisis in
geriatric mental health care during the next decades. (1) This prediction was based in part
upon the general population trends, the greater numbers of older adults being diagnosed with
late life mental illness and the increasing numbers of patients with serious mental illness
now surviving into old age. (1) This latter prediction appeared a little surprising given that
most studies of the seriously mentally ill, including patients with schizophrenia and bipolar
illness, suggested much higher mortality rates than the non-mentally ill with a reduction in
life expectancy from 13 to 30 years. (2) However there is now good evidence that the
predictions of Jeste et al are correct. The population of older patients with schizophrenia and
other severe mental disabilities is indeed increasing and likely to increase even more in the
coming decades. (3–5) The cost of mental health services for these patients has been
reported to be particularly high. (6) In an era of strained health care resources, the
significance of these trends extends beyond geriatric mental health care and is likely to have
public health implications.
These older “survivors” of schizophrenia are now likely to face the consequences of aging-
related illnesses such as cancer, dementia, and cardiovascular disease in addition to their
continued disabilities due to their mental illness. Yet there have been few comprehensive
studies of the health status of these older patients and the results of these few studies have
been inconsistent. (7–13, 6). We identified one study of health care utilization among older
adults with schizophrenia which included costs. This study, using 1999 claims data from
New Hampshire, reported that the greatest per capita expenditures for Medicare and
Medicaid were in older patients with schizophrenia and the increase was largely due to
nursing home costs. (14) In our previous study of older adults with serious mental illness,
which included schizophrenia, the seriously mentally ill had a significantly higher number of
emergency room visits and longer hospitalizations over a one year period compared to the
non-mentally ill attending the same health care facility. (13) We were unable to identify any
published studies that reported longitudinal patterns of health outcomes or costs among a
cohort of older adults with schizophrenia.
The purpose of this study is to describe health care outcomes and utilization over 10 years
among a sample of older patients with schizophrenia compared to an age matched sample of
older patients without schizophrenia. We rely on data assembled for the “Older Adult
Transitions Study” funded by the National Institutes of Health. This database was designed
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to describe the patterns of health care across the continuum of care for a large cohort of
vulnerable older adults cared for in an urban public health care system.
Methods
The “Older Adult Transitions Study” was approved by the IUPUI Institutional Review
Board and the Center for Medicare and Medicaid Services Privacy Board.
Facilities
The study site is Wishard Health Services, an urban safety net health care system providing
comprehensive services to the uninsured or underinsured in Indianapolis, IN. Wishard
Health Services includes a community mental health center that provides mental health
services across the lifespan.
Description of Dataset and Study Sample
The study sample is defined by patients who received care at Wishard Health Services from
the years 1999 to 2008 and reached the age of 65 years during that time. Clinical data for
these patients were obtained from an electronic medical record that includes, for example,
provider-assigned diagnoses, results of diagnostic testing, prescriptions, and utilization. (15)
These local data were merged with data from four additional databases throughout the same
time period: (1) Medicare claims; (2) Resident Level Minimum Data Set (MDS); (3)
Outcome and Assessment Information Set; (OASIS) and (4) Indiana Medicaid claims.
Patients’ vital status including date of death was available through the Medicare claims data.
In addition, cause of death was obtained from the Indiana State Death Certificates which
were available until 2006 through the local electronic medical record.
Identifying Older Adults With and Without a Schizophrenia Diagnosis
The total population of older adults included in the assembled datasets is 33,337 patients. Of
these patients, 31,588 reached the age of 65 between the years 1999 and 2008. Patients with
schizophrenia were defined in a two-step process to optimize the specificity of the diagnosis.
First, all patients diagnosed by any provider with an International Classification of Disease
(ICD) code indicating schizophrenia (e.g. ICD-9 code 295.x) in any of the five linked
datasets were identified (n=1635). Second, we identified the subset of patients whose
diagnosis could be traced directly to a provider in the community mental health center
(n=757). This subset of patients diagnosed with schizophrenia by a mental health specialist
constitutes our sample of schizophrenia cases. Patients with schizophrenia diagnosed in the
community mental health center were not significantly different in gender or race, but were
older (71.1 vs. 70.0).
Patients never assigned an ICD diagnosis consistent with schizophrenia comprised the
comparison sample of older adults without schizophrenia (n=30,831).
Comorbid conditions were also identified based on diagnoses and the corresponding ICD
codes assigned by providers. The conditions included: arthritis (714., 715.), diabetes (250.),
hypertension (HTN) (401.), congestive heart failure (CHF) (428., 398.91), chronic
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obstructive pulmonary disease (COPD) (491., 492., 496.), stroke (433.1, 434.1), coronary
artery disease (CAD) (410., 411., 412., 414.), cancer (140.–172. and 174.–239.), liver
disease (570., 571., 572., 573.), renal disease (585.), alcohol abuse (303.), substance abuse
(304.), thyroid disease (242., 244.) and dementia (290.0–290.43, 291.2, 294.0–294.9, 331.0–
331.9, 333.0, and 797). Information on smoking was also obtained from the electronic
medical record.
Notably, the date a subject was first diagnosed with any of the above conditions between
1999–2008 is also captured in the database. Thus, we can identify “incident” cases and dates
over time for any of the diagnoses described above. This method was used in a recent study
of the patterns of health care use among older adults with dementia using this same
database. (16) Because we know the date of birth, the date of death, and the censoring date
(December 31, 2008), we can also determine the observation window for any given patient
in the cohort.
Data Analysis
The primary purpose of the analysis was to describe the comorbidity, mortality rate, and
health care utilization and costs for older adult patients with schizophrenia in comparison
with patients without schizophrenia of similar age. We first examined demographic and
clinical characteristics of patients with and without schizophrenia. Summary statistics such
as means and standard deviations for continuous variables and proportions for categorical
variables were presented in a tabular form. Continuous variables were compared using a t
test and category variables were compared using the chi square test. Diagnoses of comorbid
conditions in patients with and without schizophrenia were compared using logistic
regression models adjusting for age, sex, and race. Proportion of cancer diagnoses were
additionally adjusted for cigarette smoking. Survival analysis was then conducted to
examine effects of schizophrenia on all-cause mortality. Herein, we modeled the time to
mortality using proportional hazard model analysis. Patients alive at the end of follow-up
were treated as censored in the analysis. The independent variable of primary interest was
schizophrenia. To assess the mortality effect of schizophrenia while accommodating the
concurrent influences of demographic, lifestyle and other comorbidities, we added the latter
characteristics as covariates. Effects of independent variables were then characterized by
hazard ratios. Kaplan-Meier estimates of the survival functions were presented graphically.
Causes of death as identified in the state death certificates were summarized and tabulated
by schizophrenia groups. For care utilization, we focused on the numbers of hospital
admissions, length of hospital stay, nursing home placement, and length of nursing home
stay. Because the utilization data were expressed as event counts (or number of days), we
used log-linear regression models to analyze the observed counts. To account for the
different lengths of observation for individual patients, we included offset parameters in the
models to indicate the duration of observation for individual patients. Similarly, we reported
the mean Medicare and Medicaid costs for the schizophrenia and non-schizophrenia groups.
Total Medicare and Medicaid expenditures for the two groups were also reported and
compared. All analyses were implemented using SAS software (Version 9.3). P values less
than or equal to 0.05 were considered statistically significant.
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To minimize the possible influences of other serious mental health conditions on the study
findings, we conducted additional sensitivity analyses by restricting the sample of patients
with schizophrenia to those whose diagnoses had been dated before or at the age of 65 years
and by excluding from the control group individuals with diagnoses of bipolar disorder (651
subjects; ICD 9 codes 296.0, 296.4, 296.5, 296.6, 296.7, 296.8) or major recurrent
depressive disorders (2361 subjects; ICD 9 code 296.3). Results of the sensitivity analysis
were then compared with the study findings.
Results
The mean number of years of follow up for the sample of patients with schizophrenia was
5.66 (SD=3.28) and for the sample without schizophrenia it was 6.69 (SD=3.26).
Demographics, comorbidities and lifestyle factors were compared between the two samples
in Table 1. The patients with schizophrenia were slightly younger, more likely to be female
and more likely to be black. They were significantly more likely to have a history of
smoking and a history of substance abuse or excessive alcohol consumption than the patients
without schizophrenia. After adjusting for demographics, the sample of patients with
schizophrenia had significantly higher rates of CHF, COPD, diabetes, and hypothyroidism.
Patients with schizophrenia had significantly lower rates of cancer and renal disease than did
patients without schizophrenia. Rates of cancer diagnoses were compared between the
groups while adjusting for age, sex, race, and smoking. The cancer rate was significantly
lower in patients with schizophrenia (30.8% vs. 43.2%; logistic regression Wald χ2[df=1] =
42.5; p<0.001). The dementia rate was doubled in patients with schizophrenia as compared
to those without schizophrenia (64.5% vs. 32.1%; χ2[df=1] = 369.2; p<0.001. After adjusting
for vascular disease and vascular risk factors, smoking, alcohol abuse, hypertension,
diabetes, CAD, CHF and stroke the effect of schizophrenia on dementia rates remained
highly significant (p<0.0001), Amongst 488 patients with schizophrenia and dementia, 248
(50.8%) had Alzheimer diagnoses (ICD-9 of 331.0). Amongst 9906 of the patients without
schizophrenia who had dementia, 4673 (47.2%) had Alzheimer diagnoses. Thus the
proportions of Alzheimer disease in the two samples were not statistically different among
those with dementia (χ2[df=1] = 2.5; p=0.1153).
There was a significant difference in mortality rates between the patients with and without
schizophrenia, as shown by the Kaplan-Meier estimates of survival functions in Figure 1.
Using proportional hazard models, we further examined the correlates of mortality in our
study sample. As shown in Table 2, schizophrenia was a significant risk factor for all-cause
mortality. Specifically, the hazard ratio associated with schizophrenia was 1.25, suggesting a
25% increase in the risk of death after controlling for the effects of other potential correlates,
including diagnoses of cancer, CHF, COPD, liver disease, alcoholism, smoking, and age
(HR: 1.25, 95% CI: 1.07–1.47, p=0.0060). In a stratified analysis of the patients with
schizophrenia, the diagnoses of dementia did not significantly increase the risk of mortality
(HR: 1.04; 95% CI: 0.68–1.59; χ2[df=1] = 0.03; p=0.860). However, in the patients without
schizophrenia, dementia increased the risk of mortality by approximately 30% (HR: 1.30,
95% CI: 1.22–1.39; χ2[df=1] = 66.7; p=<0.001).
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The primary cause of death for the two samples is shown in Table 3. Patients with
schizophrenia were more likely to die of heart disease/vascular disease and pulmonary
disease than patients without schizophrenia. They were less likely to die of cancer and other
neurological conditions such as epilepsy, Parkinson’s disease, hereditary and degenerative
nervous system conditions, and other nervous system disorders.
Table 4 shows comparative data on a number of parameters of healthcare utilization,
hospital stay, nursing home stay, and home health care. In all of the parameters involving
hospital care and nursing home stay the sample of patients with schizophrenia had
significantly higher rates of utilization. The percentage of patients receiving home health
care did not differ between the samples but within those that did receive it the patients with
schizophrenia had a significantly greater number of home health days accrued and greater
length of home health care. The mean total cost of care over the time period of the analyses
for both Medicare and Medicaid was significantly higher for the patients with schizophrenia.
In additional analyses, when hospital admissions per year are adjusted for all demographics
and comorbidities, the difference between patients with and without schizophrenia becomes
non-significant (p=0.8106). When total nursing home days are adjusted for demographics
and comorbidities the patients with schizophrenia still have significantly higher rates (p<.
0001).
Neither of the two sensitivity analyses, restricting the sample of patients with schizophrenia
to those whose diagnoses were dated before or at the age of 65 years or excluding from the
sample of patients without schizophrenia those with bipolar illness or recurrent major
disorders, led to any significant change in the results of the main analysis.
Conclusions
To our knowledge, this is the first observational cohort study of older adult patients with
schizophrenia spanning an entire decade and including data across the continuum of care.
Older adult patients with schizophrenia had a significantly greater risk for mortality than did
the older adult patients without schizophrenia even when controlling for comorbid
conditions. This finding is consistent with the results from previous studies of younger
samples. (17–20) The mean difference in survival time between the older adult patients with
and without schizophrenia at the 60th percentile was approximately 34 months. In younger
populations, differences in life expectancy have been reported between 13 to 30 years. (21)
Thus, even among patients with schizophrenia aged 65 and older, these survivors continue to
experience excess mortality. Differences in comorbidity rates between the patients with and
without schizophrenia partially explain the differences in mortality, which is consistent with
the literature in younger patients. (2, 22, 23) Some of these differences may be attributed to
the greater use of antipsychotic medication, particularly atypical antipsychotics, in the
sample of patients with schizophrenia. (24, 25) Unfortunately medication use was not
available for this analysis. However, even after controlling for the effects of demographic
factors and co-morbidities, patients with schizophrenia still had a 25% increase in mortality
risk as opposed to patients without schizophrenia. The differences in causes of death
mirrored the differences in pre-mortem diagnoses from the clinical records. Older adult
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patients with schizophrenia were significantly more likely than patients without
schizophrenia to die of heart disease and pulmonary disease but significantly less likely to
die of cancer.
The differences in rates of cancer between the two populations were striking. Previous
reports on cancer rates in patients with schizophrenia have been inconsistent. One 11 year
follow up study compared a large sample of patients with schizophrenia with figures from
the general population and found higher rates of deaths due to cancer in the population with
schizophrenia particularly for breast cancer and lung cancer. Part of the explanation for their
findings of higher rates was smoking. Their study population was younger than ours
however, with an age of 18–64 years at baseline. (8) Other studies have reported lower rates
of cancer in patients with schizophrenia, particularly in cancers of the bowel, and attributed
this to the presence of protective genes in the patients with schizophrenia or the effects of
antipsychotic medication. (10) One problem with determining cancer rates in patients with
schizophrenia is the possibility of low case identification by examining physicians, but the
finding of lower rates of cancer as a cause of death in death certificates may provide some
additional validation. In our analyses cancer diagnoses were sub-grouped according to
anatomical location. No single cancer type difference reached significance between the
groups and the lack of difference in lung cancer is particularly notable given the higher rates
of smoking in the patients with schizophrenia.
There have been prior reports identifying specific cognitive problems in younger patients
with schizophrenia. (26, 27) There are fewer studies of the effect of the aging process on
cognitive performance in aging patients with schizophrenia. (28, 29) One study reported that
the trajectory of cognitive decline was no different in community dwelling late middle-aged
patients with schizophrenia (mean age 53.1 years) than in healthy controls. (30) However,
another recent study concluded that while schizophrenia is associated with cognitive
impairment across all age groups, older patients with schizophrenia over the age of 70
experience relatively greater age-associated differences in cognitive functioning than age-
matched healthy individuals. (11) There have been remarkably few longitudinal studies of
patients with schizophrenia which included dementia as an outcome. (9) One study reported
that patients with schizophrenia are 2–3 times more likely subsequently to be diagnosed with
dementia compared to the general population. (31) In our analyses the rates of dementia in
older adult patients with schizophrenia were twice as high as in the patients without
schizophrenia (Table 1). The effect of schizophrenia on dementia rates remained highly
significant after adjusting for vascular disease and vascular risk factors, smoking, alcohol
abuse, hypertension, diabetes, CAD, CHF, and stroke. Previous post mortem studies on
older chronically hospitalized patients with schizophrenia and severe cognitive impairment
found little evidence of Alzheimer Disease pathology in their brains. (32) In our analysis an
equal proportion of patients with dementia also carried the diagnosis of Alzheimer Disease
in both the group of patients with schizophrenia and without (patients with dementia and
schizophrenia, 50.8%; patients with dementia but without schizophrenia, 47.2%). The lack
of a significant effect on mortality of the diagnosis of dementia in the patients with
schizophrenia (HR: 1.04, 95% CI: 0.68–1.59) in contrast to the increased effect of a
dementia diagnosis in the total sample (HR: 1.29, 95% CI: 1.21–1.38) raises the possibility
that at least in some cases physicians are misidentifying patients in these older, difficult-to-
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evaluate, patients with schizophrenia. The percentage of patients with dementia listed as a
cause of death did not differ between the samples although dementia is significantly
underreported in death certificates. (33, 34)
In healthcare parameters involving hospital admissions, hospital lengths of stay, nursing
home facility use, and nursing home length of stay patients with schizophrenia had
significantly greater indicators of utilization than did patients without schizophrenia. These
results are similar to previous reports. (13, 35–39) When we adjusted for patient
characteristics (demographics, comorbidity differences including dementia and life style
differences including smoking and alcohol consumption) the differences in hospital use
between the two populations were no longer significant. However, even after adjusting for
these characteristics there remained a significant difference between patients with and
without schizophrenia for nursing home days. There were no significant differences between
the samples in the percentage of patients receiving home health care but in those that did,
patients with schizophrenia had a greater number of health care days accrued and longer
lengths of stay than did the patients without schizophrenia.
The total costs for Medicare and particularly Medicaid were significantly higher for the
patients with schizophrenia compared to the patients without (see Table 4). These results are
similar to those previously reported for nursing home care by Bartels et al. (14) However,
these data highlight the magnitude of Medicaid expenditures for this population perhaps due
to a combination of the burden of schizophrenia and dementia with multiple chronic
conditions and limited socioeconomic resources. There are no evidence-based models of
care for providing integrated psychiatric and medical care for these older adults in
ambulatory, inpatient, or long-term care settings. (40, 41) Research is needed to better
design systems of care to deliver high-quality efficient care to this population across the
continuum of care. (40)
There are some significant strengths in this analysis. We believe it represents the most
comprehensive evaluation to date of these parameters in older patients with schizophrenia.
The innovation of this project is the rare, if not entirely unique, database which provides
access to a clinical electronic record coupled with Medicaid and Medicare claims as well as
data on nursing home and home healthcare stays. Obtaining information from death
certificates was also a valuable addition. In addition we did conduct two sensitivity analyses
restricting the sample of patients with schizophrenia to those whose diagnoses were dated
before or at the age of 65 years and excluded from the sample of patients without
schizophrenia those patients with bipolar illness or recurrent major disorders, neither of
which led to any significant change in the results of the main analysis.
The major limitation lies in the use of clinical records rather than direct examination,
particularly with diagnoses such as schizophrenia and dementia. The results must also be
interpreted in light of the methods we used to assemble this observational cohort. First,
patients had to survive to age 65. Second, patients do not receive standardized evaluations at
standardized intervals over time as one might find with a prospective longitudinal cohort
study. This project relies on the naturalistic observational data of a cohort of patients cared
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for in a single health care system. Thus, the data are an accurate depiction of the health care
that these patients received in a real-world clinical setting.
This analysis reinforces the concept that the increasing numbers of older seriously mentally
ill, particularly older patients with schizophrenia will create a serious burden for our health
system which will require the development of new integrated models of health care
involving links between the health and mental health systems. The possible link between
increased incidence of dementia in older patients with schizophrenia is particularly
disturbing and justifies further comprehensive study.
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Figure 1.
Kaplan-Meier Estimates of the Proportion of Mortality as a Function of Time for Patients
With and Without Schizophrenia
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Table 1
Demographics and Clinical Characteristics of Patients With and Without Schizophrenia Adjusted for Age,
Gender, and Ethnicity.
Total Sample
n=31,588
Patients with
Schizophrenia
N=757
Patients
without
Schizophrenia
N=30,831
P-value
Demographics
Age, mean (SD) 70.44 (6.81) 69.96 (6.46) 70.46 (6.82) 0.048
Female, % 59.25 69.22 59.00 <.001
Black, % 35.47 40.82 35.34 0.002
Comorbid conditions
Arthritis, % 57.97 58.26 57.96 0.317
Coronary Artery Disease, % 47.96 49.67 47.92 0.179
Cancer, % 42.88 30.78 43.18 <.001
Congestive Heart Failure, % 38.99 45.05 38.84 <.001
Chronic Obstructive 41.68 52.71 41.41 <.001
Pulmonary Disease, %
Dementia, % 32.90 64.46 32.13 <.001
Diabetes, % 45.83 55.75 45.59 <.001
Alcohol Abuse, % 5.01 14.40 4.78 <.001
Ever Smoked, % 48.50 56.56 48.02 0.003
Hypertension, % 84.72 86.92 84.67 0.462
Hyperthyroid, % 7.47 8.59 7.45 0.689
Hypothyroid, % 26.97 36.72 26.73 <.001
Liver Disease, % 14.31 12.81 14.35 0.164
Renal Disease, % 5.43 3.96 5.46 0.021
Stroke, % 17.69 17.97 17.68 0.991
Substance Abuse, % 1.38 5.42 1.28 <.001
Notes: Comparisons of age, and gender and race were based on two sample t test and chi-square tests, respectively; comparisons of comorbidities
(except for cancer) were conducted using logistic regression, adjusting for age, gender, and race. The p values were based on the Wald test with
one degree of freedom. Cancer prevalence rates in the two groups were compared using logistic regression model adjusting for age, gender, race,
and smoking status. We performed a logistic regression analysis on dementia diagnoses, additionally adjusting for the effects of vascular disease-
related risk factors, schizophrenia remained a significant factor in the analysis.
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Table 2
Demographic and Clinical Correlates of Mortality
Variable Hazard
Ratio
95% CI P-
Value
Dementia 1.29 (1.21,1.38) <.0001
Cancer 1.32 (1.25,1.39) <.0001
Coronary Artery Disease 1.05 (0.98,1.12) 0.1373
Congestive Heart Failure 1.72 (1.61,1.83) <.0001
Hypertension 0.67 (0.60,0.74) <.0001
Arthritis 0.58 (0.54,0.61) <.0001
Diabetes 1.04 (0.98,1.10) 0.2141
Hyperthyroid 0.96 (0.86,1.06) 0.4066
Chronic Obstructive Pulmonary Disease 1.28 (1.20,1.36) <.0001
Liver Disease 1.17 (1.09,1.26) <.0001
Stroke 1.02 (0.95,1.09) 0.5886
Hypothyroid 0.81 (0.76,0.87) <.0001
Renal Disease 0.96 (0.88,1.05) 0.3961
Alcohol Abuse 1.20 (1.09,1.33) 0.0003
Substance Abuse 1.20 (0.97,1.49) 0.0909
Ever Smoked 1.60 (1.51,1.70) <.0001
Black 0.97 (0.91,1.02) 0.2258
Female 0.84 (0.79,0.89) <.0001
Baseline Age 1.06 (1.06,1.07) <.0001
Schizophrenia 1.25 (1.07,1.47) 0.0060
Notes: The proportional hazard model was fitted using SAS PROC PHREG. P values were based on the Wald test with one degree of freedom.
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Table 3
Causes of Death as Identified in the State Death Certificates to 2006
Cause of Death Total Sample
N=6,332
Patients with
Schizophrenia
N=296
Patients without
Schizophrenia
N=9,806
Fisher's Exact
P-Value
Alcohol Drug Abuse, n (%) 53(0.84) 3(1.48) 50(0.82) 0.2410
Anemia, n (%) 47(0.74) 0(0.00) 47(0.77) 0.4050
Cancer, n (%) 1417(22.38) 30(14.78) 1387(22.63) 0.0080
Dementia, n (%) 438(6.92) 15(7.39) 423(6.90) 0.7780
Diabetes, n (%) 325(5.13) 10(4.93) 315(5.14) 1.0000
External Injury, n (%) 135(2.13) 1(0.49) 134(2.19) 0.1330
HIV, n (%) 3(0.05) 0(0.00) 3(0.05) 1.0000
Heart Disease/Vascular Disease, n (%) 1773(28.00) 70(34.48) 1703(27.79) 0.0390
Infection, n (%) 443(7.00) 11(5.42) 432(7.05) 0.4830
Liver, n (%) 49(0.77) 1(0.49) 48(0.78) 1.0000
Neurological, n (%) 223(3.52) 1(0.49) 222(3.62) 0.0100
Other, n (%) 274(4.33) 13(6.40) 261(4.26) 0.1570
Pulmonary, n (%) 626(9.89) 33(16.26) 593(9.68) 0.0040
Renal, n (%) 196(3.10) 6(2.96) 190(3.10) 1.0000
Stroke, n (%) 330(5.21) 9(4.43) 321(5.24) 0.7480
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Table 4
Healthcare Utilization and Healthcare Costs of Patients With and Without Schizophrenia
Total Sample
(n = 31,588)
Patients with
Schizophrenia
(n = 757)
Patients without
Schizophrenia
(n = 30,831)
P-value
Utilization
Subjects with any hospital stay, % 63.64 77.28 63.30 <.001
Total hospital days accrued, mean, (SD) 31.91 (46.54) 58.98 (94.17) 31.10 (44.08) <.001
Hospital admissions per year per 1000 patients 410 550 400 <.001
Hospital days per 1000 patients per year 2,360 5,290 2,290 <.001
Subjects with any nursing facility use, % 31.56 56.41 30.95 <.001
Total nursing home days accrued, mean, (SD) 116.31 (370.93) 479.47 (802.39) 107.39 (349.09) <.001
Nursing facility days per 1000 patients per year 16,600 68,580 15,370 <.001
Nursing facility length of stay, mean, (SD) 159.55 (355.54) 471.34 (922.22) 145.59 (299.24) <.001
Subjects with any home health care use, % 33.37 31.31 33.42 0.224
Total home health care days accrued, mean (SD) 57.11 (206.70) 74.12 (243.70) 56.69 (205.70) 0.092
Home health care days per 1000 patients per year 8,290 10,820 8,230 0.046
Home health care length of stay, mean (SD) 79.21 (490.20) 78.55 (490.38) 107.79 (482.33) <.001
Healthcare Cost
Medicare, mean (SD) 50153.19 (70894.88) 63335.01 (78866.89) 49829.53 (70658.32) <.001
Medicaid, mean (SD) 22655.95 (76891.31) 130954.01 (198627.40) 19996.80 (69245.28) <.001
Note: Care utilization measures were analyzed using log-linear models. P values were based on the Wald test with one degree of freedom. Cost was
analyzed using t test.
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